Overview A Study of LY2835219 in Japanese Participants With Advanced Cancer Status: Completed Trial end date: 2019-08-21 Target enrollment: Participant gender: Summary The main purpose of this study is to evaluate safety and side effects of LY2835219 in Japanese participants with advanced cancer. Phase: Phase 1 Details Lead Sponsor: Eli Lilly and Company